{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:59:54Z","timestamp":1790675994293,"version":"4.1.0"},"reference-count":43,"publisher":"Tech Science Press","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Cytokine Netw"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1684\/ecn.2019.0429","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T17:49:34Z","timestamp":1697824174000},"page":"39-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Role of IL-33 in transplant biology"],"prefix":"10.32604","volume":"30","author":[{"given":"Ying","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqiang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"key":"429_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0002-9440(10)63631-0","volume":"163","author":"ES Baekkevold","year":"2003","unstructured":"Baekkevold ES, Roussigne M, Yamanaka T, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003; 163: 69\u201379.","journal-title":"Am J Pathol"},{"key":"429_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","volume":"23","author":"J Schmitz","year":"2005","unstructured":"Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1- like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479\u201390.","journal-title":"Immunity"},{"key":"429_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nri2692","volume":"10","author":"FY Liew","year":"2010","unstructured":"Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010; 10: 103\u201310.","journal-title":"Nat Rev Immunol"},{"key":"429_CR4","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.4049\/jimmunol.179.4.2551","volume":"179","author":"AA Chackerian","year":"2007","unstructured":"Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007; 179: 2551\u20135.","journal-title":"J Immunol"},{"key":"429_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-9255-8-22","volume":"8","author":"AM Miller","year":"2011","unstructured":"Miller AM. Role of IL-33 in inflammation and disease. J Inflamm 2011; 8: 22.","journal-title":"J Inflamm"},{"key":"429_CR6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1097\/TP.0b013e3181d720af","volume":"89","author":"H Yin","year":"2010","unstructured":"Yin H, Li XY, Jin XB, et al. IL-33 prolongs murine cardiac allograft survival through induction of TH2-type immune deviation. Transplantation 2010; 89: 1189\u201397.","journal-title":"Transplantation"},{"key":"429_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3389\/fimmu.2015.00232","volume":"6","author":"T Gajardo Carrasco","year":"2015","unstructured":"Gajardo Carrasco T, Morales RA, Perez F, et al. Alarmin\u2019 immunologists: IL-33 as a putative target for modulating t celldependent responses. Front Immunol 2015; 6: 232.","journal-title":"Front Immunol"},{"key":"429_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/intimm\/dxr006","volume":"23","author":"J Louten","year":"2011","unstructured":"Louten J, Rankin AL, Li Y, et al. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol 2011; 23: 307\u201315.","journal-title":"Int Immunol"},{"key":"429_CR9","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3389\/fimmu.2018.01476","volume":"9","author":"M Fanny","year":"2018","unstructured":"Fanny M, Nascimento M, Baron L, et al. The IL-33 receptor ST2 regulates pulmonary inflammation and fibrosis to bleomycin. Front Immunol 2018; 9: 1476.","journal-title":"Front Immunol"},{"key":"429_CR10","doi-asserted-by":"publisher","first-page":"E9362","DOI":"10.1073\/pnas.1803613115","volume":"115","author":"LR Lopetuso","year":"2018","unstructured":"Lopetuso LR, De Salvo C, Pastorelli L, et al. IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. Proc Natl Acad Sci U S A 2018; 115: E9362\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"429_CR11","doi-asserted-by":"publisher","first-page":"3858032","DOI":"10.1155\/2018\/3858032","volume":"2018","author":"E Di Salvo","year":"2018","unstructured":"Di Salvo E, Ventura-Spagnolo E, Casciaro M, Navarra M, Gangemi S. IL-33\/IL-31 axis: a potential inflammatory pathway. Mediat Inflamm 2018; 2018: 3858032.","journal-title":"Mediat Inflamm"},{"key":"429_CR12","doi-asserted-by":"publisher","first-page":"eaan8355","DOI":"10.1126\/scisignal.aan8355","volume":"10","author":"B Serrels","year":"2017","unstructured":"Serrels B, McGivern N, Canel M, et al. IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks. Sci Signal 2017; 10: pii: eaan8355.","journal-title":"Sci Signal"},{"key":"429_CR13","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1158\/0008-5472.CAN-16-1602","volume":"77","author":"M Fang","year":"2017","unstructured":"Fang M, Li Y, Huang K, et al. IL33 promotes colon cancer cell stemness via JNK activation and macrophage recruitment. Cancer Res 2017; 77: 2735\u201345.","journal-title":"Cancer Res"},{"key":"429_CR14","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3389\/fimmu.2018.01179","volume":"9","author":"H Chen","year":"2018","unstructured":"Chen H, Chen Y, Liu H, Que Y, Zhang X, Zheng F. Integrated expression profiles analysis reveals correlations between the IL- 33\/ST2 axis and CD8(+) T cells, regulatory T cells, and myeloidderived suppressor cells in soft tissue sarcoma. Front Immunol 2018; 9: 1179.","journal-title":"Front Immunol"},{"key":"429_CR15","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1093\/cvr\/cvy166","volume":"114","author":"R Altara","year":"2018","unstructured":"Altara R, Ghali R, Mallat Z, Cataliotti A, Booz GW, Zouein FA. Conflicting vascular and metabolic impact of the IL-33\/sST2 axis. Cardiovasc Res 2018; 114: 1578\u201394.","journal-title":"Cardiovasc Res"},{"key":"429_CR16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1161\/HYPERTENSIONAHA.118.11157","volume":"72","author":"R Ghali","year":"2018","unstructured":"Ghali R, Altara R, Louch WE, et al. IL-33 (interleukin 33)\/sST2 (soluble suppression of tumorigenicity 2) axis in hypertension and heart failure. Hypertension 2018; 72: 818\u201328.","journal-title":"Hypertension"},{"key":"429_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nri1882","volume":"6","author":"GK Hansson","year":"2006","unstructured":"Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6: 508\u201319.","journal-title":"Nat Rev Immunol"},{"key":"429_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1084\/jem.20071868","volume":"205","author":"AM Miller","year":"2008","unstructured":"Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205: 339\u201346.","journal-title":"J Exp Med"},{"key":"429_CR19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/j.1432-2277.2011.01306.x","volume":"24","author":"SM Brunner","year":"2011","unstructured":"Brunner SM, Schiechl G, Falk W, Schlitt HJ, Geissler EK, Fichtner-Feigl S. Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int 2011; 24: 1027\u201339.","journal-title":"Transpl Int"},{"key":"429_CR20","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/labinvest.2016.54","volume":"96","author":"C Dai","year":"2016","unstructured":"Dai C, Lu FN, Jin N, et al. Recombinant IL-33 prolongs leflunomide-mediated graft survival by reducing IFN-gamma and expanding CD4(+)Foxp3(+) T cells in concordant heart transplantation. Lab Investig 2016; 96: 820\u20139.","journal-title":"Lab Investig"},{"key":"429_CR21","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.4049\/jimmunol.1100519","volume":"187","author":"HR Turnquist","year":"2011","unstructured":"Turnquist HR, Zhao Z, Rosborough BR, et al. IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 2011; 187: 4598\u2013610.","journal-title":"J Immunol"},{"key":"429_CR22","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/bja\/aeu556","volume":"114","author":"IA Hilmi","year":"2015","unstructured":"Hilmi IA, Damian D, Al-Khafaji A, et al. Acute kidney injury following orthotopic liver transplantation: incidence, risk factors, and effects on patient and graft outcomes. Br J Anaesth 2015; 114: 919\u201326.","journal-title":"Br J Anaesth"},{"key":"429_CR23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.23736\/S0375-9393.16.11661-X","volume":"83","author":"P Angeli","year":"2017","unstructured":"Angeli P, Bezinover D, Biancofiore G, et al. Acute kidney injury in liver transplant candidates: a position paper on be half of the Liver Intensive Care Group of Europe. Minerva Anestesiol 2017; 83: 88\u2013101.","journal-title":"Minerva Anestesiol"},{"key":"429_CR24","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1097\/TP.0000000000002305","volume":"102","author":"F Durand","year":"2018","unstructured":"Durand F, Francoz C, Asrani SK, et al. Acute kidney injury after liver transplantation. Transplantation 2018; 102: 1636\u201349.","journal-title":"Transplantation"},{"key":"429_CR25","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1681\/ASN.2010091011","volume":"22","author":"A Akcay","year":"2011","unstructured":"Akcay A, Nguyen Q, He Z, et al. IL-33 exacerbates acute kidney injury. J Am Soc Nephrol 2011; 22: 2057\u201367.","journal-title":"J Am Soc Nephrol"},{"key":"429_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejphar.2017.06.031","volume":"812","author":"H Liang","year":"2017","unstructured":"Liang H, Xu F, Wen XJ, et al. Interleukin-33 signaling contributes to renal fibrosis following ischemia reperfusion. Eur J Pharmacol 2017; 812: 18\u201327.","journal-title":"Eur J Pharmacol"},{"key":"429_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/mmr.2015.4516","volume":"13","author":"F Yang","year":"2016","unstructured":"Yang F, Zhu P, Duan L, Yang L, Wang J. IL33 and kidney disease (review). Mol Med Rep 2016; 13: 3\u20138.","journal-title":"Mol Med Rep"},{"key":"429_CR28","doi-asserted-by":"publisher","first-page":"E783","DOI":"10.3390\/ijms18040783","volume":"18","author":"WY Chen","year":"2017","unstructured":"Chen WY, Li LC, Yang JL. Emerging roles of IL-33\/ST2 axis in renal diseases. Int J Mol Sci 2017; 18. pii: E783.","journal-title":"Int J Mol Sci"},{"key":"429_CR29","doi-asserted-by":"publisher","first-page":"611","DOI":"10.12659\/AOT.899263","volume":"21","author":"J Zhang","year":"2016","unstructured":"Zhang J, Wang Z, Xu Z, et al. The potential role of IL-33 in renal transplant recipients with chronic allograft dysfunction. Ann Transplant 2016; 21: 611\u20138.","journal-title":"Ann Transplant"},{"key":"429_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.gene.2017.11.010","volume":"644","author":"Z Xu","year":"2018","unstructured":"Xu Z, Zhao C, Wang Z, et al. Interleukin-33 levels are elevated in chronic allograft dysfunction of kidney transplant recipients and promotes epithelial to mesenchymal transition of human kidney (HK-2) cells. Gene 2018; 644: 113\u201321.","journal-title":"Gene"},{"key":"429_CR31","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1681\/ASN.2017060650","volume":"29","author":"M Ferhat","year":"2018","unstructured":"Ferhat M, Robin A, Giraud S, et al. Endogenous IL-33 contributes to kidney ischemia-reperfusion injury as an alarmin. J Am Soc Nephrol 2018; 29: 1272\u201388.","journal-title":"J Am Soc Nephrol"},{"key":"429_CR32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1684\/ecn.2018.0410","volume":"29","author":"C Liu","year":"2018","unstructured":"Liu C, Chen J, Liu B, et al. Role of IL-18 in transplant biology. Eur Cytokine Netw 2018; 29: 48\u201351.","journal-title":"Eur Cytokine Netw"},{"key":"429_CR33","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.neuron.2015.01.013","volume":"85","author":"SP Gadani","year":"2015","unstructured":"Gadani SP, Walsh JT, Smirnov I, Zheng J, Kipnis J. The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. Neuron 2015; 85: 703\u20139.","journal-title":"Neuron"},{"key":"429_CR34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nri.2016.95","volume":"16","author":"FY Liew","year":"2016","unstructured":"Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol 2016; 16: 676\u201389.","journal-title":"Nat Rev Immunol"},{"key":"429_CR35","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3389\/fimmu.2018.02308","volume":"9","author":"MH Ferhat","year":"2018","unstructured":"Ferhat MH, Robin A, Barbier L, et al. The impact of invariant NKT cells in sterile inflammation: the possible contribution of the alarmin\/cytokine IL-33. Front Immunol 2018; 9: 2308.","journal-title":"Front Immunol"},{"key":"429_CR36","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/hep.25768","volume":"56","author":"N Sakai","year":"2012","unstructured":"Sakai N, Van Sweringen HL, Quillin RC, et al. Interleukin-33 is hepatoprotective during liver ischemia\/reperfusion in mice. Hepatology 2012; 56: 1468\u201378.","journal-title":"Hepatology"},{"key":"429_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.09.010","volume-title":"J Hepatol","author":"HO Yazdani","year":"2017","unstructured":"Yazdani HO, Chen HW, Tohme S, et al. IL-33 exacerbates liver sterile inflammation by amplifying neutrophil extracellular trap formation. J Hepatol 2017;. doi: https:\/\/doi.org\/10.1016\/j.jhep.2017.09.010."},{"key":"429_CR38","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1111\/j.1582-4934.2009.00801.x","volume":"14","author":"P Marvie","year":"2010","unstructured":"Marvie P, Lisbonne M, L\u2019Helgoualc\u2019h A, et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med 2010; 14: 1726\u201339.","journal-title":"J Cell Mol Med"},{"key":"429_CR39","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.3389\/fimmu.2018.02432","volume":"9","author":"OS Kotsiou","year":"2018","unstructured":"Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33\/ST2 axis in organ fibrosis. Front Immunol 2018; 9: 2432.","journal-title":"Front Immunol"},{"key":"429_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fimmu.2017.00475","volume":"8","author":"B Griesenauer","year":"2017","unstructured":"Griesenauer B, Paczesny S. The ST2\/IL-33 axis in immune cells during inflammatory diseases. Front Immunol 2017; 8: 475.","journal-title":"Front Immunol"},{"key":"429_CR41","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1016\/j.jss.2010.04.004","volume":"163","author":"GA Roth","year":"2010","unstructured":"Roth GA, Zimmermann M, Lubsczyk BA, et al. Up-regulation of interleukin 33 and soluble ST2 serum levels in liver failure. J Surg Res 2010; 163: e79\u201383.","journal-title":"J Surg Res"},{"key":"429_CR42","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.immuni.2013.07.018","volume":"39","author":"T McHedlidze","year":"2013","unstructured":"McHedlidze T, Waldner M, Zopf S, et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 2013; 39: 357\u201371.","journal-title":"Immunity"},{"key":"429_CR43","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/cmi.2016.63","volume":"15","author":"Z Tan","year":"2018","unstructured":"Tan Z, Liu Q, Jiang R, et al. Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells. Cell Mol Immunol 2018; 15: 388\u201398.","journal-title":"Cell Mol Immunol"}],"container-title":["European Cytokine Network"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ecn.2019.0429.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1684\/ecn.2019.0429\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ecn.2019.0429.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.jle.com\/10.1684\/ecn.2019.0429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:27:34Z","timestamp":1790674054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/ECN\/v30n2\/65393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1684\/ecn.2019.0429","relation":{},"ISSN":["1952-4005"],"issn-type":[{"value":"1952-4005","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"28 M\u00e4rz 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Disclosure\n                      . The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}